Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Diclovol Retard 100mg tablets (Arun Pharm)
1001010C0CCADAF
|
Diclovol | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Diclovol Retard 100mg tablets (Mylan)
1001010C0CCAFAF
|
Diclovol | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Diclozip 25mg gastro-resistant tablets
1001010C0BIAAAD
|
Diclozip | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Diclozip 50mg gastro-resistant tablets
1001010C0BIABAE
|
Diclozip | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Difflam-P 3% cream
1003020F0BBABAA
|
Difflam (Topical) | Benzydamine hydrochloride | Musculoskeletal and Joint Diseases | No data available |
|
Diflunisal 250mg tablets
1001010D0AAAAAA
|
Diflunisal | Diflunisal | Musculoskeletal and Joint Diseases | No data available |
|
Diflunisal 500mg tablets
1001010D0AAABAB
|
Diflunisal | Diflunisal | Musculoskeletal and Joint Diseases | No data available |
|
Distamine 125mg tablets
1001030F0BBABAE
|
Distamine | Penicillamine | Musculoskeletal and Joint Diseases | No data available |
|
Distamine 250mg tablets
1001030F0BBACAF
|
Distamine | Penicillamine | Musculoskeletal and Joint Diseases | No data available |
|
Dolobid 250mg tablets
1001010D0BBAAAA
|
Dolobid | Diflunisal | Musculoskeletal and Joint Diseases | No data available |
|
Dolobid 500mg tablets
1001010D0BBABAB
|
Dolobid | Diflunisal | Musculoskeletal and Joint Diseases | No data available |
|
Dubam cream
1003020N0BEACA0
|
Dubam | Methyl salicylate | Musculoskeletal and Joint Diseases | No data available |
|
Dubam spray
1003020N0BEABAM
|
Dubam | Methyl salicylate | Musculoskeletal and Joint Diseases | No data available |
|
Dulbalm cream
100302000BBBWA0
|
Proprietary compound preparation BNF 1003020 | Other rubefacient and topical antirheumatic preparations | Musculoskeletal and Joint Diseases | No data available |
|
Dyloject 75mg/2ml solution for injection vials
1001010C0CLAABI
|
Dyloject | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Dysman 250 capsules
1001010N0BDACAA
|
Dysman | Mefenamic acid | Musculoskeletal and Joint Diseases | No data available |
|
Dysman 500 tablets
1001010N0BDADAD
|
Dysman | Mefenamic acid | Musculoskeletal and Joint Diseases | No data available |
|
Ebetrex 10mg/1ml solution for injection pre-filled syringes
1001030U0BFABBB
|
Ebetrex (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | No data available |
|
Ebetrex 15mg/1.5ml inj pre-filled syringes
1001030U0BFACBC
|
Ebetrex (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | No data available |
|
Ebetrex 20mg/1ml solution for injection pre-filled syringes
1001030U0BFAGBS
|
Ebetrex (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | No data available |
|
Ebetrex 25mg/1.25ml inj pre-filled syringes
1001030U0BFADBP
|
Ebetrex (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | No data available |
|
Ebetrex 30mg/1.5ml inj pre-filled syringes
1001030U0BFAFBR
|
Ebetrex (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | No data available |
|
Ebetrex 7.5mg/0.75ml inj pre-filled syringes
1001030U0BFAAAZ
|
Ebetrex (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | No data available |
|
Ebretin 200mg capsules
1001010E0BDAAAA
|
Ebretin | Etodolac | Musculoskeletal and Joint Diseases | No data available |
|
Ebretin 300mg capsules
1001010E0BDABAC
|
Ebretin | Etodolac | Musculoskeletal and Joint Diseases | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.